Efficacy and Tolerability of Subcutaneous Sumatriptan for Acute Migraine: A Comparison Between Ethnic Groups

Burke-Ramirez, P.; Asgharnejad, Mahnaz; Webster, CJ; Davis, Randy; Laurenza, Antonio

doi:10.1046/j.1526-4610.2001.01159.x

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 23 randomized trials of subcutaneous sumatriptan . Fifteen placebo controlled studies revealed large and consistent statistically significant differences between sumatriptan and placebo in four class 1 studies, seven class 2 studies, and four class 3 studies …”

Section: Resultsmentioning

confidence: 99%

Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies

et al. 2016

View full text Add to dashboard Cite

Objective.-To provide evidence-based treatment recommendations for adults with acute migraine who require treatment with injectable medication in an emergency department (ED). We addressed two clinically relevant questions: (1) Which injectable medications should be considered first-line treatment for adults who present to an ED with acute migraine? (2) Do parenteral corticosteroids prevent recurrence of migraine in adults discharged from an ED?Methods.-The American Headache Society convened an expert panel of authors who defined a search strategy and then performed a search of Medline, Embase, the Cochrane database and clinical trial registries from inception through 2015. Identified articles were rated using the American Academy of Neurology's risk of bias tool. For each medication, the expert panel determined likelihood of efficacy. Recommendations were created accounting for efficacy, adverse events, availability of alternate therapies, and principles of medication action.Results/Conclusions.-The search identified 68 unique randomized controlled trials utilizing 28 injectable medications. Of these, 19 were rated class 1 (low risk of bias), 21 were rated class 2 (higher risk of bias), and 28 were rated class 3 (highest risk of bias). Metoclopramide, prochlorperazine, and sumatriptan each had multiple class 1 studies supporting acute efficacy, as did dexamethasone for prevention of headache recurrence. All other medications had lower levels of evidence.Recommendations.-Intravenous metoclopramide and prochlorperazine, and subcutaneous sumatriptan should be offered to eligible adults who present to an ED with acute migraine (Should offer-Level B). Dexamethasone should be offered to these patients to prevent recurrence of headache (Should offer-Level B). Because of lack of evidence demonstrating efficacy and concern about sub-acute or long-term sequelae, injectable morphine and hydromorphone are best avoided as first-line therapy (May avoid-Level C).

show abstract

Section: Resultsmentioning

confidence: 99%

Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition, experimental studies have suggested that ethnic minorities report greater pain than whites in response to the administration of calibrated noxious stimuli in a laboratory setting [9,10]. Ethnic differences also exist in the prevalence and severity of chronic pain [11], with African American and Hispanic patients reporting more pain from cancer [12], spinal injury [13], vulvodynia [14], migraine [15], arthritis [16], and nonspecific chronic pain [17,18]. Moreover, a population‐based study indicated that both Hispanic and African American women reported greater pain than white women [19], although not all studies are consistent in demonstrating this pattern of effects [20,21].…”

Section: Introductionmentioning

confidence: 99%

Ethnic Similarities and Differences in the Chronic Pain Experience: A Comparison of African American, Hispanic, and White Patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In addition to utilization, it is important to consider whether ethnic differences exist for managing migraine. A recent study found that African Americans, Hispanics, and Caucasians responded similarly to triptans 23 . Thus, one would expect treatment regimens (eg, prescribing migraine‐specific medications or migraine preventive medications as appropriate) to be similar.…”

mentioning

confidence: 99%

Migraine Care Among Different Ethnicities: Do Disparities Exist?

Nicholson¹,

Rooney²,

Vo³

et al. 2006

Headache

View full text Add to dashboard Cite

Migraine utilization, diagnosis, and treatment were low for both groups. However, this was especially true for African Americans, who also reported lower levels of trust and communication with doctors relative to Caucasians. The findings highlight the need for improved physician and patient education about migraine diagnosis and treatment, the importance of cultural variation in pain presentation, and the importance of communication when diagnosing and treating migraine.

show abstract

Efficacy and Tolerability of Subcutaneous Sumatriptan for Acute Migraine: A Comparison Between Ethnic Groups

Cited by 3 publications

References 14 publications

Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies

Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies

Ethnic Similarities and Differences in the Chronic Pain Experience: A Comparison of African American, Hispanic, and White Patients

Migraine Care Among Different Ethnicities: Do Disparities Exist?

Contact Info

Product

Resources

About